Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for retinal vascular pressure in type 2 diabetes with early diabetic kidney disease
ChiCTR1900027931Phase 4Not yet recruiting
- Sponsor
- Tianjin People's Hospital
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (2 arms), sponsored by Tianjin People's Hospital. Primary endpoint: retinal vascular pressure. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR1900027931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027931.